Imunon (IMNN) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

IMNN Imunon

Watchlist

0.693
+0.009+1.32%

Close Nov 21 16:00 ET

0.716
+0.023+3.26%

Post 16:01 ET

10.05MMarket Cap-362P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Imunon Price Target Cut to $12.00/Share From $14.00 by HC Wainwright & Co.
Dow JonesNov 11 13:32 ET · Ratings
Imunon Is Maintained at Buy by HC Wainwright & Co.
Dow JonesNov 11 13:32 ET · Ratings
Express News | Watching Imunon; Zacks Small-Cap Research Gives Stock $8 Price Valuation
BenzingaNov 11 11:00 ET
Imunon, Inc. (IMNN) Q3 2024 Earnings Call Transcript Summary
moomoo AINov 7 17:24 ET · Conference Call
Imunon, Inc. (IMNN) Q3 2024 Earnings Call Transcript
Earnings Call TranscriptsNov 7 17:11 ET
Imunon Announces Positive Data From Phase 2 Trial Of IMNN-001 In Advanced Ovarian Cancer, Stock Down
RTTNewsNov 7 10:37 ET

Comments

73690864

Nov 12 14:31

$Imunon (IMNN.US)$ lol pr today is target price cut from 14 to 12 dollars, while this ish has been trading at .80 cents.

Teddy123

Nov 7 09:17

IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting

$Imunon (IMNN.US)$
2025
LAWRENCEVILLE, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced the presentation of new clinical data from the recently completed Phase 2 OVATION 2 Study of IMNN-001, its investigational interleukin-12 (IL-12) immunoth...

Jaguar8

Nov 7 09:01

NEWS

$Imunon (IMNN.US)$
IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting
IMUNON announced positive Phase 2 OVATION 2 trial results for IMNN-001 in advanced ovarian cancer. The study of 112 patients showed that IMNN-001 plus standard chemotherapy improved overall survival by 35% (40.5 vs 29.4 months) and progression-free survival by 25% (14.9 vs 11.9 months) compared to chemotherapy alone. The treatment demonstr...